About EyePoint Pharmaceuticals, Inc.
https://eyepointpharma.comEyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom.
CEO
Jay S. Duker
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-12-09 | Reverse | 1:10 |
| 2008-06-11 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 92
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
CORMORANT ASSET MANAGEMENT, LP
Shares:8.32M
Value:$132.53M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:6.19M
Value:$98.59M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:5.56M
Value:$88.51M
Summary
Showing Top 3 of 163
About EyePoint Pharmaceuticals, Inc.
https://eyepointpharma.comEyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $966K ▼ | $62.27M ▼ | $-59.73M ▼ | -6.18K% ▼ | $-0.85 | $-59.16M ▲ |
| Q2-2025 | $5.33M ▼ | $67.39M ▼ | $-59.43M ▼ | -1.11K% ▼ | $-0.85 ▼ | $-61.69M ▼ |
| Q1-2025 | $24.45M ▲ | $72.48M ▲ | $-45.2M ▼ | -184.82% ▲ | $-0.65 ▼ | $-48.34M ▼ |
| Q4-2024 | $11.59M ▲ | $56.01M ▲ | $-41.4M ▼ | -357.26% ▼ | $-0.64 ▼ | $-40.83M ▼ |
| Q3-2024 | $10.52M | $42.54M | $-29.36M | -278.99% | $-0.54 | $-28.95M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $204.02M ▼ | $251.69M ▼ | $51.51M ▼ | $200.18M ▼ |
| Q2-2025 | $255.73M ▼ | $301.15M ▼ | $55.14M ▼ | $246.01M ▼ |
| Q1-2025 | $318.19M ▼ | $362.56M ▼ | $64.17M ▼ | $298.4M ▼ |
| Q4-2024 | $370.91M ▲ | $418.46M ▲ | $81.96M ▼ | $336.5M ▲ |
| Q3-2024 | $253.79M | $300.92M | $82.18M | $218.73M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-59.73M ▼ | $-59.35M ▲ | $55.38M ▲ | $7.4M ▲ | $3.43M ▲ | $-60.15M ▲ |
| Q2-2025 | $-59.43M ▼ | $-62.59M ▼ | $48.34M ▲ | $238K ▲ | $-14.02M ▲ | $-63.81M ▼ |
| Q1-2025 | $-45.2M ▼ | $-53.12M ▼ | $39.52M ▲ | $-951K ▼ | $-14.55M ▼ | $-53.4M ▼ |
| Q4-2024 | $-41.4M ▼ | $-35.85M ▲ | $-95.96M ▼ | $151.69M ▲ | $19.87M ▲ | $-36.23M ▲ |
| Q3-2024 | $-29.36M | $-39.03M | $16.2M | $11.89M | $-10.94M | $-40.6M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 License And Collaboration Agreement | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ | $0 ▼ |
 Product | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Royalty | $0 ▲ | $10.00M ▲ | $0 ▼ | $0 ▲ |
 Y U T I Q Product | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Jay S. Duker
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2020-12-09 | Reverse | 1:10 |
| 2008-06-11 | Reverse | 1:4 |
ETFs Holding This Stock
Summary
Showing Top 3 of 92
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
CORMORANT ASSET MANAGEMENT, LP
Shares:8.32M
Value:$132.53M
SUVRETTA CAPITAL MANAGEMENT, LLC
Shares:6.19M
Value:$98.59M
ADAGE CAPITAL PARTNERS GP, L.L.C.
Shares:5.56M
Value:$88.51M
Summary
Showing Top 3 of 163